• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Nautilus Biotechnology to Announce Third Quarter 2024 Financial Results on October 29, 2024

    10/8/24 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $NAUT alert in real time by email

    SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the third quarter 2024 before market open on Tuesday, October 29, 2024.

    The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio.

    About Nautilus Biotechnology, Inc.

    With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus' mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.

    Media Contact

    [email protected]

    Investor Contact

    [email protected]



    Primary Logo

    Get the next $NAUT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NAUT

    DatePrice TargetRatingAnalyst
    12/5/2024$1.75Neutral → Sell
    Goldman
    6/27/2024$6.00Buy
    Guggenheim
    6/3/2024$3.00Hold
    Jefferies
    1/6/2022$8.00Equal-Weight
    Morgan Stanley
    11/2/2021Outperform
    Cowen & Co.
    8/4/2021$10.00Neutral
    Goldman Sachs
    7/13/2021$13.00Buy
    Jefferies
    More analyst ratings

    $NAUT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nautilus Biotechnology Reports Second Quarter 2025 Financial Results

    SEATTLE, July 31, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2025. "In Q2, we achieved major milestones that underscore the continued advancement of our platform," said Sujal Patel, CEO of Nautilus Biotechnology. "Not only did we continue our momentum across both targeted and broadscale proteomic development efforts, but we also publicly shared the first scientific manuscript to feature novel data generated using the Nautilus Platform. The manuscript represents nearly a decade of pioneering work by our team and

    7/31/25 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnology Announces Agreement with the Allen Institute, Further Validating its Approach to Single-Molecule Proteomics

    • Allen Institute to employ Iterative Mapping, Nautilus' single-molecule proteomics method, to investigate connection between tau protein and Alzheimer's disease • Agreement links the organizations' next-generation proteomics technology and neuroscience leadership to potentially unlock breakthrough therapeutics and biomarkers for neurodegenerative disease SEATTLE, July 30, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering single-molecule proteome analysis, today announced they have entered into an agreement with the Allen Institute focused on investigating the connection between the tau protein and neurodegenerative conditions such

    7/30/25 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025

    SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter 2025 before market open on Thursday, July 31, 2025. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters i

    7/15/25 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $NAUT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Epperly Melissa B,

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    6/25/25 4:37:40 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Director Posard Matthew L.

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    6/25/25 4:37:28 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Director Mcilwain Matthew S

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    6/25/25 4:37:16 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $NAUT
    SEC Filings

    View All

    SEC Form 10-Q filed by Nautilus Biotechnolgy Inc.

    10-Q - Nautilus Biotechnology, Inc. (0001808805) (Filer)

    7/31/25 4:35:28 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnolgy Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Nautilus Biotechnology, Inc. (0001808805) (Filer)

    7/30/25 7:45:56 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnolgy Inc.

    SCHEDULE 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

    6/24/25 4:42:31 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $NAUT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO and Treasurer Mowry Anna bought $11,488 worth of shares (15,000 units at $0.77), increasing direct ownership by 22% to 83,000 units (SEC Form 4)

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    6/2/25 5:12:33 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Scientist Mallick Parag bought $9,885 worth of shares (13,500 units at $0.73), increasing direct ownership by 0.07% to 20,493,392 units (SEC Form 4)

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    5/12/25 7:19:33 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    CEO, President, and Secretary Patel Sujal M bought $76,918 worth of shares (77,233 units at $1.00), increasing direct ownership by 0.77% to 10,141,721 units (SEC Form 4)

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    3/21/25 4:44:37 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $NAUT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nautilus Biotechnology downgraded by Goldman with a new price target

    Goldman downgraded Nautilus Biotechnology from Neutral to Sell and set a new price target of $1.75

    12/5/24 7:46:35 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Guggenheim initiated coverage on Nautilus Biotechnology with a new price target

    Guggenheim initiated coverage of Nautilus Biotechnology with a rating of Buy and set a new price target of $6.00

    6/27/24 7:49:37 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Jefferies resumed coverage on Nautilus Biotechnology with a new price target

    Jefferies resumed coverage of Nautilus Biotechnology with a rating of Hold and set a new price target of $3.00

    6/3/24 8:53:10 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $NAUT
    Leadership Updates

    Live Leadership Updates

    View All

    Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer

    SEATTLE, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for comprehensively quantifying the proteome, today announced the appointment of Kentaro (Ken) Suzuki as Chief Marketing Officer. Mr. Suzuki joins Nautilus after 25 years in product and marketing leadership roles at Agilent Technologies, most recently serving as Vice President and General Manager of Agilent's Mass Spectrometry division. He has held numerous leadership positions at Agilent, including in the Strategic Program Office and Certified Pre-Owned Instruments, CrossLab Services and Support, and Spectroscopy. "Ke

    9/17/24 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development

    SEATTLE, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the expansion of its research and development senior leadership team with the appointment of Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development. Dr. Huber brings to Nautilus over 20 years of experience in biotechnology start-ups both in Europe and the US, most recently as founder, CTO and, ultimately, CEO of Quantapore, a company devoted to pioneering massively parallel, direct, single-molecule DNA and protein analytical tools. Prior to that, he he

    11/1/23 8:05:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnology Appoints Eric Spence as Vice President of Instrument Engineering and Ken Kuhn, Ph.D., as Vice President of Reagent and Platform Development

    SEATTLE, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced further expansion of its management team with the appointments of Eric Spence as Vice President of Instrument Engineering and Ken Kuhn, Ph.D., as Vice President of Reagent and Platform Development. Both executives join the company's product development team. Eric Spence, Vice President of Instrument Engineering: Instrument engineering veteran Eric Spence comes to Nautilus from Genapsys, where he advanced through several positions of increasing responsibility leading the instrum

    8/1/22 4:05:00 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $NAUT
    Financials

    Live finance-specific insights

    View All

    Nautilus Biotechnology Reports Second Quarter 2025 Financial Results

    SEATTLE, July 31, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2025. "In Q2, we achieved major milestones that underscore the continued advancement of our platform," said Sujal Patel, CEO of Nautilus Biotechnology. "Not only did we continue our momentum across both targeted and broadscale proteomic development efforts, but we also publicly shared the first scientific manuscript to feature novel data generated using the Nautilus Platform. The manuscript represents nearly a decade of pioneering work by our team and

    7/31/25 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025

    SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter 2025 before market open on Thursday, July 31, 2025. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters i

    7/15/25 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnology Reports First Quarter 2025 Financial Results

    SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2025. "In Q1, we saw continued development progress based on the results of internal verification and validation work we've done on our Tau proteoform assay," said Sujal Patel, CEO of Nautilus Biotechnology. "The assay's reproducibility, accuracy, dynamic range, and sample compatibility align closely with our anticipated launch specifications and with the requirements we continue to hear from potential customers and partners. We are confident that 202

    4/29/25 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $NAUT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Nautilus Biotechnolgy Inc.

    SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

    11/14/24 4:31:50 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13D/A filed by Nautilus Biotechnolgy Inc. (Amendment)

    SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

    11/16/23 9:18:26 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13D/A filed by Nautilus Biotechnolgy Inc. (Amendment)

    SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

    3/1/23 3:30:45 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials